Dental implants is a highly cyclical business. It’s an underlying high-growth sector, especially in the U.S. and other markets where the population is aging, but is correlated to consumers’ ability to pay out of their disposable income.
During the crunch, as one would expect, many potential patients put off treatment, opting instead for cheaper alternatives such as crowns and bridges, or indeed doing nothing at all. As a result, revenues fell, profitability was trimmed and stocks in the space got hammered.
The very short-term outlook doesn’t look bright either. But a private equity (PE) powerhouse such as Kohlberg Kravis Roberts and Co. or a consortium comprising say Bridgepoint Capital, Permira and Cinven could bet on a cycle upswing, with growth accelerating and valuations returning to mid-cycle levels of around 20x Ebitda by 2013–not to mention the expected efficiencies that PE ownership would bring, which in turn would boost the PE exit. That is if the cycle does happen as the current bears say.
No comments:
Post a Comment